CytoMed Therapeutics Holds Annual Shareholders Meeting

Ticker: GDTC · Form: 6-K · Filed: May 24, 2024 · CIK: 1873093

Cytomed Therapeutics LTD 6-K Filing Summary
FieldDetail
CompanyCytomed Therapeutics LTD (GDTC)
Form Type6-K
Filed DateMay 24, 2024
Risk Levellow
Pages6
Reading Time7 min
Key Dollar Amounts$90,000, $70,000
Sentimentneutral

Sentiment: neutral

Topics: reporting, shareholder-meeting, foreign-private-issuer

TL;DR

CytoMed held its shareholder meeting May 15th, filing its 6-K.

AI Summary

CytoMed Therapeutics Limited held its Annual Shareholders Meeting on May 15, 2024, at 11:00 a.m. local time. The company is a foreign private issuer filing a Form 6-K report for the month of May 2024, indicating it will file annual reports under cover of Form 20-F.

Why It Matters

This filing confirms the company's adherence to reporting requirements and provides a date for a key corporate governance event.

Risk Assessment

Risk Level: low — This filing is a routine report of a foreign private issuer and does not contain significant new financial or operational information.

Key Players & Entities

FAQ

What is the exact date and time the Annual Shareholders Meeting was held?

The Annual Shareholders Meeting was held on May 15, 2024, at 11:00 a.m. local time.

What type of filing is this Form 6-K for?

This is a Report of Foreign Private Issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934.

Which form will CytoMed Therapeutics Limited use for its annual reports?

CytoMed Therapeutics Limited will file annual reports under cover of Form 20-F.

What is the principal executive office address of CytoMed Therapeutics Limited?

The principal executive office is located at 1 Commonwealth Lane #08-22 Singapore 149544.

When was the company's former name changed?

The former company name, CytoMed Therapeutics Pte. Ltd., was changed on July 16, 2021.

Filing Stats: 1,705 words · 7 min read · ~6 pages · Grade level 8.5 · Accepted 2024-05-24 11:12:06

Key Financial Figures

Filing Documents

SIGNATURES

SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized. Date: May 24, 2024 CytoMed Therapeutics Limited By: /s/ CHOO Chee Kong Name: CHOO Chee Kong Title: Director and Chairman 6

View Full Filing

View this 6-K filing on SEC EDGAR

View on Read The Filing